Riluzole prevents ischemic spinal cord injury caused by aortic crossclamping  by Lang-Lazdunski, Loic et al.
dures.1 The cellular and molecular mechanisms that
underlie hypoxic-ischemic injury to the spinal cord
have not been totally elucidated, but recent studies sug-
gest that the release of excitatory amino acids by
ischemic cells into the extracellular space of the central
nervous system may contribute substantially to neu-
ronal death.2,3
Glutamate is thought to be the primary excitatory
amino acid in the spinal cord, and it may destroy neu-
ronal cells through its actions on N-methyl-D-aspartate
(NMDA) and non-NMDA receptors by inducing mas-
sive sodium and calcium ion influxes into the cell,
resulting in neuronal death.4,5 Microdialysis studies
have confirmed that an elevation in glutamate level is
induced by spinal cord ischemia.3 Although the neuro-
protective effects of NMDA receptor antagonists have
S pinal cord ischemia remains a devastating compli-cation of thoracoabdominal aortic operations, with
paraplegia occurring after as many of 31% of proce-
Background: Recent studies support the involvement of glutamate neuro-
toxicity in the pathophysiology of spinal cord injury induced by aortic
crossclamping. We investigated the effects of riluzole, a neuroprotective
drug that blocks glutamatergic neurotransmission, in a rabbit model of
spinal cord ischemia. Methods: The infrarenal aortas of New Zealand
White albino rabbits (n = 40) were occluded for 40 minutes.
Experimental groups were as follows: sham operation group (n = 5),
control group undergoing occlusion but receiving no pharmacologic
intervention (n = 10), experimental group A (n = 10) receiving 8 mg/kg
riluzole intravenously 30 minutes before ischemia, experimental group
B (n = 10) receiving 4 mg/kg riluzole intravenously 30 minutes before
ischemia and at the onset of reperfusion, and experimental group C (n
= 10) receiving 8 mg/kg riluzole intravenously at the onset of reperfu-
sion. Neurologic status was assessed at 6, 24, and 48 hours after the
operation and then daily until the fifth day. All animals were killed at 24,
48, or 120 hours after the operation. Spinal cords were harvested for
histopathologic studies, immunohistochemical studies for microtubule-
associated protein 2, and search for morphologic features of apoptosis
by the terminal deoxynucleotidyltransferase-mediated deoxyuridine
triphosphate–biotin nick-end labeling staining method. Results: All ani-
mals in the control group became paraplegic. Except for 1 rabbit in
group C, all riluzole-treated animals had better neurologic function.
Luxol fast blue and terminal deoxynucleotidyltransferase-mediated
deoxyuridine triphosphate–biotin nick-end labeling staining methods
demonstrated typical morphologic changes characteristic of necrosis
and apoptosis in control animals. Riluzole prevented or attenuated
ischemia-induced necrosis, apoptosis, and cytoskeletal proteolysis,
depending on the dose and the timing of administration. Conclusion:
Riluzole may have therapeutic utility during high-risk operations on the
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RILUZOLE PREVENTS ISCHEMIC SPINAL CORD INJURY CAUSED BY AORTIC CROSSCLAMPING
been demonstrated both in vitro and in vivo,6,7 their
pronounced side effects limit their clinical use.7,8
Riluzole (2-amino-6-trifluoromethoxy benzothia-
zole) is a neuroprotective drug that inhibits both sodi-
um and calcium ion channels,9,10 activates a new class
of background potassium ion channels,11 and blocks
glutamatergic neurotransmission in the central nervous
system by noncompetitively blocking the NMDA
receptor.12,13 Riluzole has demonstrated anti-ischemic
properties in several models of focal and global cere-
bral ischemia13-15 and is currently in clinical use among
patients with amyotrophic lateral sclerosis.16,17 It seems
devoid of major side effects, suggesting that it might be
of use in clinical situations involving spinal cord
ischemia.
The aim of this study was to determine whether rilu-
zole administered before or after aortic occlusion was
capable of preserving the structural integrity of the
spinal cord in a well-established model of severe
ischemia.18 In this setting it appeared worthwhile to
determine whether riluzole could prevent ischemia-
induced apoptosis19 and degradation of microtubule-
associated protein 2 (MAP2), a cytoskeletal protein
responsible for maintaining the structural integrity of
the neuron and an early marker of cytoplasmic damage
induced by spinal cord injury.20
Materials and methods
Animal care and surgical technique. We used female
New Zealand White albino rabbits (Charles River Labora-
tories, Inc, Wilmington, Mass) weighing 3.5 to 4.5 kg.
Animal care and experiments complied with the “Guide for
the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources and published by
the National Institutes of Health (NIH Publication No. 86-23,
revised 1985). Animals were anesthetized by the intramuscu-
lar administration of 50 mg/kg ketamine and 10 mg/kg
xylazine. Animals were allowed to breath spontaneously, and
general anesthesia was maintained by inhalation of 1%
halothane mixed with oxygen administered by face cone at a
rate of 6 L/min. After placement of 24-gauge ear vein and
artery catheters, a flank incision was made and the infrarenal
aorta was exposed through a retroperitoneal approach.
Intravenous heparin (150 U/kg) was given and spinal cord
ischemia was induced by crossclamping of the aorta with
surgical microclamps (Biover vessel clips; Arex, Palaiseau,
France) for 40 minutes. Arterial blood pressure and heartbeat
were continuously monitored throughout the procedure
(Hewlett-Packard monitor model 78353B; Hewlett-Packard
Company, Palo Alto, Calif). Percutaneous arterial oxygen sat-
uration was continuously monitored. Body temperature was
continuously monitored with a flexible probe inserted 3 cm
into the rectum. Core temperature was registered from the
onset of anesthesia to 1 hour after reperfusion and supported
by a heating lamp throughout the procedure. The aortic cross-
clamps were removed after 40 minutes and the flank was
closed in 2 layers. The bladders of the paraplegic animals
were emptied twice daily with the Credé maneuver. Animals
in the sham operation group (n = 5) were killed 3 hours after
exposure of the aorta without crossclamping of the vessel.
Animals were randomly assigned to be killed at 24, 48, or
120 hours. All animals were killed with a lethal intraperi-
toneal injection of 200 mg/kg pentobarbital. Spinal cords
were quickly removed for histopathologic and immunohisto-
chemical examinations. The L4-L5 segment was fixed in
Holland Bouin solution. The L6-L7 segment was frozen in
isopentane on dry ice and stored at –70°C.
Drug treatment. Riluzole (Research Biochemicals
International, distributed by Bioblock Scientific, Illkirsch,
France) was first dissolved in 0.1 N hydrochloric acid and
then diluted in 0.9% saline solution. It was injected intra-
venously in all groups of rabbits. Experimental group A ani-
mals (n = 10) received 8 mg/kg riluzole 30 minutes before
aortic occlusion. Experimental group B animals (n = 10)
received 4 mg/kg riluzole 30 minutes before aortic occlusion
and at the onset of reperfusion. Experimental group C ani-
mals received 8 mg/kg riluzole at the onset of reperfusion.
Control animals (n = 10) underwent standard aortic occlusion
and intravenous injection of 0.9% sodium chloride 30 min-
utes before ischemia (volume and conditions identical to
those of riluzole injection). A separate sham operation group
(n = 3) received 8 mg/kg riluzole to verify that the drug itself
did not induce histologic changes in the spinal cord.
Evaluation of neurologic outcome. Neurologic status was
scored by assessment of hind limb neurologic function
according to the Tarlov scale21 (0, no movement; 1, slight
movement; 2, sits with assistance; 3, sits alone; 4, weak hop;
5, normal hop) at 24, 48, or 120 hours after ischemia. Two
observers (1 of whom was blinded to the experimental condi-
tions) graded the neurologic status independently.
Statistical analysis. Statistical analyses of physiologic and
hemodynamic parameters were performed by analysis of vari-
ance for repeated measures. All hemodynamic data are
expressed as mean ± SD. Statistical analyses of the neurologic
scores were done with the nonparametric Mann-Whitney U test.
Tissue preparation. For paraffin sections, spinal cords
(L4-L5 segments) were removed and immersed in Holland
Bouin solution for 24 hours. Specimens were dehydrated in
alcohol 95% for 30 minutes, followed by 4 changes of 100%
alcohol for 1 hour each and 5 changes of toluene for 1 hour
each under vacuum at 37°C. Spinal cords were infiltrated
with paraffin (4 changes of paraffin for 1 hour each) and
embedded in paraffin at 57°C under vacuum and pressure.
Sections were cut on a microtome (Leica Technology BV,
Rijswijk, The Netherlands) at 7 m m.
For cryostat sections, spinal cords (L6-L7 segments) were
quickly extracted and freshly frozen in isopentane at –45°C.
Cryostat coronal sections (10 m m) were mounted on poly-L-
lysine–coated slides and tissue was postfixed by successive
immersions in 0.01 mol/L phosphate-buffered saline solution
(PBS) and 4% paraformaldehyde for 30 minutes. Sections
were then dehydrated in ethanol baths (50%, 70%, and
100%), air dried, and stored at –70°C until use.
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All spinal cords were divided into 2 groups, 1 for frozen
sections and 1 for paraffin sections. For each spinal cord stud-
ied 6 sections were placed on 3-aminopropylethoxysi-
lane–coated slides and 10 slides per rabbit (randomly chosen)
were used in each stage of the analysis. All samples
processed for histopathologic and immunohistochemical
experiments were taken from animals examined for function-
al recovery. The neuropathologist, who was blinded to exper-
imental conditions, performed the histologic assessment by
means of light microscopy.
Histopathologic examination. The Klüver-Barrera Luxol
fast blue staining method22 was used. Transverse 7-m m sec-
tions were deparaffinized by washing twice in xylene for 5
minutes each and heating at 56°C overnight and were then
rehydrated through a graded series of alcohols and distilled
water. Sections were soaked in 70% alcohol for 10 minutes.
They were stained at 57°C for 16 hours in solution A, con-
taining 1 mg Luxol fast blue (Solvent Blue 38; Sigma
Chemical Co, St Louis, Mo) and 5 mL 10% acetic acid in
1000 mL 95% alcohol. Sections were then rinsed in 95%
alcohol and distilled water. They were differentiated by being
dipped singly into 0.05% aqueous lithium carbonate solution
for a few seconds, then washed through several changes of
70% alcohol, and then placed in distilled water. Sections
were then counterstained with neutral red stain (Sigma).
Sections were treated with 0.2% sodium bisulfite for 1
minute and then immersed in 0.1 mol/L acetate buffer (pH
5.6) for 1 minute. Neutral red staining was performed in solu-
tion B, containing 3 volumes of 0.05% neutral red stock solu-
tion and 2 volumes of 0.1 mol/L acetate buffer, for 15 min-
utes at room temperature. Sections were rinsed in distilled
water, immersed in copper sulfate–chrome alum solution for
1 second, and rinsed in distilled water. Sections were then
mounted in Aquamount (Biomeda, Foster City, Calif).
DNA nick-end labeling by terminal deoxynucleotidyltrans-
ferase-mediated deoxyuridine triphosphate–biotin nick-end
labeling (TUNEL) reaction was also used. Coronal 10-m m
frozen sections were used and processed according to the
TUNEL method.23 In brief, sections were rehydrated in
ethanol (95%, 70%, and 50%) followed by PBS and bathed in
0.3% hydrogen peroxide in methanol to inactivate endogenous
peroxidase. Sections were then rendered permeable in 0.3%
polysorbate and PBS and washed twice in PBS before appli-
cation of the TUNEL reaction mixture (in situ cell death
detection kit, distributed by Hoffmann-La Roche Ltd, Basel,
Switzerland). Positive control was obtained by advance incu-
bation of a section with DNase I (20 m g/mL) for 15 minutes at
room temperature before incubation with biotinylated
deoxyuridine triphosphate. All slides were incubated in a
humid chamber at 37°C for 2 hours. Sections were then
washed twice in PBS and allowed to incubate overnight at 4°C
with the secondary antifluorescein-peroxidase conjugate. On
the following day sections were washed 3 times with PBS and
the peroxidase labeling was revealed with 3-amino-9-ethyl
carbazole by means of the VectaStain ABC kit (Vector
Laboratories, Inc, Burlingame, Calif). After a final rinse in
distilled water, sections were coverslipped.
Immunohistochemical examination for microtubule-
associated protein-2. Frozen sections (25 m m) were
immersed in 0.3% hydrogen peroxide and PBS for 10 min-
utes, blocked with 5% goat serum (Vector Laboratories, dis-
tributed by BIOSYS, Compiegne, France) and 3% Triton for
1 hour at room temperature, and then rinsed in PBS 1X.
Sections were then incubated with the primary antibody
overnight. The antiserum used for the study of cytoskeletal
protein expression (microtubule-associated protein-2
[MAP2]) was a monoclonal mouse anti-MAP2 (clone HM-2,
diluted 1:500; Sigma). After the primary incubation and 3
rinses in PBS 1X, sections were then incubated in biotinylat-
ed horse antimouse immunoglobulin G (diluted 1:100; Vector
Laboratories) for 3 hours. MAP2 expression was visualized
by 3´-diaminobenzidine and nickel chloride staining with the
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Table I. Neurologic status at 24 hours after ischemia
Sham 
Tarlov operation Control A*† B*‡ C§ 
score (n = 5) (n = 10) (n = 10) (n = 10) (n = 10)
0 — 10 — — 1
1 — — — 1 3
2 — — 3 — 1
3 — — 2 — —
4 — — — 1 4
5 5 — 5 8 1
Neurologic status was scored by assessment of hind limb neurologic functions
according to the Tarlov scale21 (0, no movement; 1, slight movement; 2, sits
with assistance; 3, sits alone; 4, weak hop; 5, normal hop). Experimental
groups were as follows: sham operation group with no aortic crossclamping,
control group receiving no pharmacologic intervention, experimental group A
(n = 10) receiving 8 mg/kg riluzole intravenously 30 minutes before ischemia,
experimental group B (n = 10) receiving 4 mg/kg riluzole intravenously 30
minutes before ischemia and at the onset of reperfusion, experimental group C
(n = 10) receiving 8 mg/kg riluzole intravenously at the onset of reperfusion.
*P = .0001 compared with control group by Mann-Whitney U test.
†P = .2004 compared with experimental group B by Mann-Whitney U test.
‡P = .0044 compared with experimental group C by Mann-Whitney U test.
§P = .0003 compared with control group by Mann-Whitney U test.
Table II. Physiologic parameters
Control A B C 
(n = 10) (n = 10) (n = 10) (n = 10)
Weight (kg) 3.92 ± 0.8 3.89 ± 0.9 4 ± 0.7 3.94 ± 0.8
Rectal temperature*
(°C)
Maximum 39.2 ± 0.5 39.2 ± 0.3 39.3 ± 0.2 39.4 ± 0.3
Minimum 38.3 ± 0.6 38.3 ± 0.3 38.4 ± 0.4 38.3 ± 0.2
Heart rate 
(beats/min)
Maximum 192 ± 7 195 ± 7 191 ± 12 192 ± 16
Minimum 153 ± 13 143 ± 14 142 ± 9 151 ± 23
Mean arterial blood 92 ± 14 93 ± 17 105 ± 18 101 ± 12
pressure (mm Hg)
Values are expressed as mean ± SD. Groups are as given in the footnote to
Table I.
*Maximum and minimum rectal temperatures were taken from those recorded
from the onset of anesthesia to 1 hour of reperfusion.
VectaStain ABC kit (Vector Laboratories). All sections were
washed a final time, in PBS 1X and then in distilled water,
and mounted with glycerol.
Results
Neurologic outcomes. The results are summarized in
Table I. At 24 hours after 40 minutes of ischemia, all
rabbits in the control group (n = 10) showed paralysis
of the hind limbs (Tarlov score of 0). Riluzole treat-
ment remarkably enhanced the recovery of motor func-
tion in the hind limbs. Except for 1 rabbit in group C,
all animals treated with riluzole demonstrated signifi-
cantly better neurologic scores after reperfusion than
did untreated (control) rabbits. The best result was
obtained with animals that received 4 mg/kg riluzole 30
minutes before aortic occlusion and at the onset of
reperfusion (group B). Eighty percent of group B ani-
mals showed intact neurologic function (Tarlov score
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Fig 1. Representative photomicrographs of lumbar spinal cord sections stained with the Klüver-Barrera staining
method from rabbits in sham operation (A and B), control (saline solution treatment, C and D), and experimen-
tal riluzole treatment (E and F) groups. All but sham operation group underwent 40 minutes of ischemia and 5
days of reperfusion. Chosen section for illustration of spinal cords in riluzole-treated rabbits is that of a rabbit
with Tarlov score of 5 that was treated 30 minutes before aortic occlusion and at onset of reperfusion. A and B,
Normal appearance of motor neurons in ventral horn of rabbits in sham operation group. C and D, Necrotic motor
neurons in ventral horn of control rabbits. E and F, Ventral horn motor neurons of riluzole-treated rabbits appear
completely normal.
of 5). This experimental group showed a significantly
better recovery of neurologic function than that of
experimental group C, which was treated with 8 mg/kg
riluzole after ischemia (P < .01).
Physiologic and hemodynamic parameters. Phys-
iologic parameters are presented in Table II. Rectal
temperature, heart rate, and mean arterial blood pres-
sure were not affected by the administration of riluzole.
There were no statistical differences in the physiologic
parameters of the animals among the 4 experimental
groups. Arterial oxygen saturation was within the ref-
erence range in all animals.
Histopathologic examination and terminal deoxy-
nucleotidyltransferase-mediated deoxyuridine tri-
phosphate–biotin nick-end labeling staining.
Klüver-Barrera and TUNEL staining methods were
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Fig 2. Representative photomicrographs show morphologic features of apoptosis with TUNEL staining in lum-
bar spinal cord sections from rabbits in sham operation (A and B), control (saline solution treatment, C and D),
and experimental riluzole treatment (E and F) groups. All but sham operation group underwent 40 minutes of
ischemia and 5 days of reperfusion. Chosen section for illustration of spinal cords in riluzole-treated rabbits is
that of a rabbit with Tarlov score of 5 that was treated 30 minutes before aortic occlusion and at onset of reper-
fusion. TUNEL-staining cells are characterized by a strong perinuclear graining pattern in gray (white arrow) and
white (black arrow) matter of spinal cord. No TUNEL-staining cells could be detected in sham operation (A and
B) or riluzole treatment (E and F) groups. Control rabbit spinal cords exhibited numerous TUNEL-staining neu-
rons and glial cells in both gray and white matter (C and D).
used to characterize necrosis and apoptosis, respective-
ly, occurring in spinal cord injury after ischemia. Fig 1
shows representative Klüver-Barrera staining examples
observed in the white and gray matter of the spinal cord
in animals killed 5 days after the ischemic insult. No
sign of neuronal damage was observed in the spinal
cords of rabbits in the sham operation group (Fig 1, A
and B). After 40 minutes of spinal cord ischemia, typi-
cal morphologic changes characteristic of necrosis
appeared in paraplegic rabbits (Fig 1, C and D). Injured
spinal cord showed invasion of white blood cells into
gray and white matter, cellular disruption and vac-
uolization of the gray matter, presence of shrunken
necrotic neurons in ventral and dorsal horn gray matter,
and infiltration by polymorphonuclear neutrophils and
monocytes at 5 days after ischemia. Riluzole treatment
almost completely protected spinal cord against the
effects of ischemia. Fig 1, E and F, shows that signs of
necrosis were not present in the spinal cords of rilu-
zole-treated animals (group B), which appeared histo-
logically comparable to the spinal cords of rabbits in
the sham operation group.
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Fig 3. MAP2 immunoreactivity in lumbar spinal cord sections from rabbits in sham operation (A and B), control
(saline solution treatment, C and D), and experimental riluzole treatment (E and F) groups. All but sham opera-
tion group underwent 40 minutes of ischemia and 5 days of reperfusion. Chosen section for illustration of spinal
cords in riluzole-treated rabbits is that of a rabbit with Tarlov score of 5 that was treated 30 minutes before aor-
tic occlusion and at onset of reperfusion. Intense MAP2 immunoreactivity was observed in dendrites and neu-
ronal soma (arrow) of rabbits in sham operation (A and B) and riluzole treatment (C and D) groups. Control rab-
bit spinal cords (C and D) exhibited complete losses of MAP2 immunoreactivity in ventral and dorsal horns.
Apoptosis characterized by chromatin condensation,
DNA fragmentation, nuclear shrinkage, and fragmenta-
tion of nuclear bodies (apoptotic bodies) was visualized
by the in situ TUNEL technique. Fig 2, C and D, shows
the presence of TUNEL-staining nuclei in gray and
white matter of the spinal cord 48 hours after ischemia,
whereas none of the nuclei in the control preparation
showed TUNEL labeling (Fig 2, A and B). Most
TUNEL-staining neurons were located in dorsal horns
and intermediate gray matter. No motor neurons were
found to stain with TUNEL. Riluzole treatment signifi-
cantly prevented ischemia-induced apoptosis in all sec-
tors of the spinal cord. Fig 2, E and F, demonstrates the
lack of apoptotic nuclei in white and gray matter of the
spinal cord at 48 hours of reperfusion in a riluzole-treat-
ed animal (group B). Most animals in groups A and B
had no injury or minimal injury of the motor neurons,
whereas 50% of the animals in group C had significant
injury of the motor neurons (>50% necrotic neurons).
There were no differences in the locations of TUNEL-
staining neurons among animals in groups A, B, and C.
However, animals in group C had more TUNEL-stain-
ing cells in intermediate gray matter and dorsal horns
than did animals in groups A and B.
Cytoskeletal proteolysis. The cytoskeletal element
MAP2 located in neuronal soma and dendrites is
involved in maintaining neuronal structural integrity,
which is essential for normal cellular function and sur-
vival. Cytoskeletal degradation is highly sensitive to glu-
tamate- and calcium ion–mediated excitotoxic events
leading to activation of calcium ion–dependent phos-
phatases and proteases.20 Fig 3, A and B, shows that the
spinal cords of animals in the sham operation group
exhibited intense perikaryal and dendritic MAP2
immunoreactivity. Aortic occlusion led to a rapid
cytoskeletal protein degradation in control animals (Fig
3, C and D.) As early as 24 hours after spinal cord
ischemia there was a loss of MAP2 antigenicity in cell
bodies and dendrites of ischemic spinal cord neurons in
control animals (Fig 3, C and D). Riluzole treatment pre-
vented or attenuated the cytoskeletal proteolysis in the
ischemic spinal cords, depending on the timing of admin-
istration and dose. Fig 3, E and F, shows that in spinal
cord–injured rabbits treated with riluzole, MAP2
immunoreactivity was comparable to that in animals in
the sham operation group. Administration of riluzole to a
separate group of rabbits that underwent sham operation
(n = 3) had no effect on MAP2 labeling (data not shown).
Discussion
Numerous surgical techniques and pharmacologic
interventions have been used to reduce the rate of peri-
operative paraplegia after operations on the thoracoab-
dominal aorta, but none can claim consistently proven
efficacy.24 This report is the first to provide evidence
that riluzole administered before or after aortic occlu-
sion improves the neurologic status and preserves
spinal cord integrity. The rabbit model of spinal cord
ischemia used in this study is a reliable and repro-
ducible model for producing neurologic deficits18 and
testing drugs that might serve to protect the spinal cord
from ischemic injury. Occlusion of the infrarenal aorta
for 40 minutes leads to complete paraplegia, with
Tarlov scores of 0, in all control animals. To assess the
impressive neuroprotective effect of riluzole, the motor
function of the hind limbs was scored and the necrotic
and apoptotic neuronal cell deaths associated with
changes in the expression of MAP2 cytoskeletal pro-
tein induced by ischemia were analyzed in the spinal
cords of both control and treated animals.
Evidence has accumulated that the excitatory amino
acids, particularly glutamate, have potent neurotoxic
activity during such conditions of depleted cellular ener-
gy as hypoxia and ischemia.4,5 The ischemia-induced
overaccumulation of glutamate and other excitatory
amino acids in the extracellular space of the central ner-
vous system leads to excessive excitation of the NMDA
and non-NMDA receptors, leading to a rise in intracel-
lular calcium that triggers proteases, lipases, protein
kinase C, nitric oxide synthase, endonucleases, altered
gene transcription, and release of free radicals, eventual-
ly producing neuronal injury and death.4 Much attention
has recently focused on NMDA and non-NMDA recep-
tor antagonists, which have been shown to be neuropro-
tective in several models of cerebral or spinal cord
ischemia.2-6 Some of these compounds have major side
effects, however, limiting their clinical use.7,8,25
Riluzole is a neuroprotective drug, although its exact
molecular target has not been yet identified. An impor-
tant and probably indirect effect of riluzole is the inhi-
bition of presynaptic glutamate release.12,13 This inhi-
bition, which leads to a neuroprotective effect, is
probably linked to the capacity of riluzole to inhibit
both sodium and calcium ion voltage-sensitive chan-
nels9,10 and to activate a new class of background
potassium ion channels that are highly expressed in the
spinal cord.11 At the postsynaptic level riluzole is prob-
ably effective on the same types of ion channels and
would thus prevent some of the deleterious postsynap-
tic effects of glutamate by opening background potas-
sium ion channels11 and producing postsynaptic hyper-
polarization by increasing magnesium ion blockade of
NMDA receptors.26 In addition, a brief report recently
indicated that administration of riluzole after spinal
cord injury improves mitochondrial function and
increases sodium ion–dependent glutamate reuptake.27
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In vivo, riluzole has demonstrated neuroprotective
action in several models of neurodegenerative disease,
such as Parkinson and Huntington diseases,28-30 cerebral
ischemia,14,15,31 and traumatic spinal cord injury.20,32 It
has also been reported that riluzole at the dose used in
this work (8 mg/kg) attenuates both neurologic motor
and cognitive dysfunction after experimental brain
injury.33 This report demonstrates that riluzole treatment
results in improved spinal cord protection in a setting of
severe ischemia. The analysis of the neurologic status
demonstrates that the tolerance of the spinal cord to
ischemia was significantly improved by riluzole in the 3
experimental groups. The best protection was obtained
when riluzole was administered before ischemia; how-
ever, riluzole afforded significant protection even when
administered shortly after ischemia. An intravenous
injection of riluzole 30 minutes before aortic occlusion
and at the onset of reperfusion led to the best Tarlov
score and prevented paraplegia in almost 100% of ani-
mals, despite a 40-minute ischemic insult. Histologic
examination of the spinal cords revealed either no evi-
dence or very little evidence of injury in riluzole-treated
rabbits, whereas spinal cords from control animals had
evidence of extensive spinal cord injury with central
gray matter necrosis, vacuolization, Nissl substance dis-
solution, eosinophilic cytoplasm, and monocyte and
macrophage infiltration. This study also provides evi-
dence that 40 minutes of ischemia resulted in the degra-
dation of cytoskeletal MAP2, which is known to be an
early event after spinal cord injury,20 and that riluzole
treatment totally prevented MAP2 breakdown. This
observation suggests that the spinal cord really is pro-
tected against ischemia-induced necrosis.
In addition to necrosis, neuronal cell death induced
by ischemia also occurred through apoptosis. Pro-
grammed cell death, or apoptosis, is defined morpho-
logically and biochemically by cellular shrinkage,
chromatin condensation, and internucleosomal frag-
mentation of DNA.19 Apoptosis is the mode of cellular
death that occurs during the normal development of tis-
sues, including the spinal cord, and it has recently been
demonstrated to be an important mode of cellular death
in the ischemic spinal cord.19 In this study apoptotic
cell death was detected by the observation of positive-
ly stained nuclei with the in situ end-labeling procedure
(TUNEL method). Abundant TUNEL-staining cells
were observed in ischemic spinal cords 48 hours after
ischemia; again, riluzole treatment prevented apoptotic
cell damage. In addition to establishing that riluzole is
an antiapoptotic drug, these results indirectly establish
a role for glutamate in the initiation of apoptotic cell
death in spinal cord neurons.
Riluzole has been reported to slightly decrease body
temperature when injected intravenously.13 It is well
demonstrated that even mild hypothermia can increase
the duration of ischemia tolerated34 by modulating the
release of excitatory amino acids and by reducing the
spinal cord metabolic rate for oxygen.35 In this study the
body temperature was monitored in all animals from the
moment that they were anesthetized to the moment that
they were returned to their cages. All rabbits had a mild
decrease in body temperature, but there was no signifi-
cant difference between control and riluzole-treated ani-
mals. Hypothermia therefore does not account for the
protective effects of riluzole seen in this study.
We anticipate that riluzole might have important clin-
ical implications. This drug may be administered either
prophylactically to patients undergoing high-risk thora-
coabdominal aortic operations or curatively to patients
with a ruptured aortic aneurysm or an aortic dissection
and an evolving neurologic deficit. In the latter situa-
tion, riluzole might improve the neurologic outcome of
patients by blocking the excitotoxic cascade in the
spinal cord and by preserving numerous viable neurons
while patients are undergoing emergency operation for
aortic replacement and spinal cord revascularization.
Riluzole does nothing by itself to reestablish perfu-
sion to ischemic areas. In the case of a neurologic
deficit caused by aortic dissection, this drug would
simply buy time until reperfusion could be established.
Riluzole (100-200 mg/day) was made available for
amyotrophic lateral sclerosis therapy in 1995. The drug
has a few side effects, such as asthenia, mild sedative
effects, and, more rarely, liver dysfunction.25,36 Some
of these side effects might be more frequent at the
doses of riluzole used in this study (8 mg/kg), but they
should not limit the clinical application of riluzole as
an acute treatment in the prevention of spinal cord
injury during thoracoabdominal aortic operations.
We thank Frank Aguila and Yvette Benhamou for technical
assistance. We thank Hôpital FOCH for use of the
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